Wegovy for Fatty Liver Disease (MASH): The First GLP-1 Approved for Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis — MASH, formerly known as NASH — is a progressive liver disease that affects an estimated 14.9 million adults in the US. It's driven by the same metabolic dysfunction that drives obesity and type 2 diabetes. Left untreated, MASH can progress to cirrhosis, liver failure, and the need for transplant.

With the August 2025 approval, Wegovy became the first GLP-1 receptor agonist indicated for liver disease — and only the second medication approved for MASH overall, joining resmetirom (Rezdiffra).

ESSENCE Trial Results

The approval is based on Part 1 of the ESSENCE trial, which studied semaglutide 2.4mg weekly injection in adults with MASH and stage F2–F3 liver fibrosis (moderate to advanced, but not cirrhosis).

What This Means for Insurance Coverage

Like the Zepbound/sleep apnea pathway, the MASH approval creates a new coverage route. Patients with diagnosed MASH and fibrosis may be able to get Wegovy covered under their plan's liver disease benefit — even if the same plan excludes weight-loss drugs.

This requires a confirmed MASH diagnosis, typically through liver biopsy or non-invasive fibrosis assessment (FIB-4 score, elastography). Talk to your hepatologist or GI specialist about whether this pathway applies to you.

Does Compounded Semaglutide Have the Same Effect on the Liver?

The same active molecule — semaglutide — is present in both brand-name Wegovy and compounded formulations. The ESSENCE trial used the brand-name 2.4mg weekly injection. While the pharmacological mechanism should be equivalent, the FDA approval, clinical trial data, and insurance coverage pathway are tied to Wegovy specifically.

If you're already on compounded semaglutide and have concerns about fatty liver disease, mention it to your provider. GLP-1 medications generally improve liver fat and inflammation markers regardless of whether the source is brand or compounded — but the formal MASH indication and its insurance implications only apply to the brand-name product.

Limitations of the Approval

• This is an accelerated approval — confirmatory data from Part 2 of the ESSENCE trial is expected in 2029
• Not approved for patients with cirrhosis (F4 fibrosis)
• Must be used with reduced-calorie diet and increased physical activity
• The approval is for the injectable Wegovy formulation at 2.4mg — not the oral pill

The GLP-1 Indication Expansion

Between sleep apnea (Zepbound), cardiovascular risk reduction (Wegovy), and now MASH (Wegovy), GLP-1 medications are accumulating FDA approvals that reframe them from "weight loss drugs" to "metabolic disease treatments." This shift matters because each new indication expands insurance coverage pathways and strengthens the medical rationale for prescribing.